Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) is a clinical-stage biotherapeutics pioneer developing novel medicines for serious inflammatory, fibrotic, and immunological conditions. This news hub provides investors and industry professionals with centralized access to verified corporate announcements and scientific updates.
Track PRTC's progress through key developments including clinical trial milestones, regulatory submissions, and strategic partnerships. Our curated collection features official press releases on therapeutic advancements across the company's pipeline, particularly in gastrointestinal disorders, oncology, and neurological diseases.
Stay informed about PRTC's unique approach to modulating the adaptive human system through its Wholly-Owned Programs and Founded Entities structure. All content maintains strict editorial standards to ensure accuracy and compliance with financial disclosure regulations.
Bookmark this page for direct access to PureTech Health's latest verified updates, including research publications, patent filings, and partnership announcements. Check regularly for new developments in this innovative biopharma company's pursuit of transformative therapies.
PureTech Health (NASDAQ: PRTC) has published new research in BMC Pulmonary Medicine revealing critical insights into the experiences of people living with Idiopathic Pulmonary Fibrosis (IPF). The study, conducted with 106 IPF patients across the US, highlighted significant challenges in diagnosis, treatment, and quality of life.
Key findings include varied diagnosis timelines with frequent delays, low antifibrotic treatment uptake, and challenges in managing multiple health conditions. Nearly 90% of participants reported managing additional health challenges alongside IPF. The research also revealed that while supplemental oxygen therapy provides symptom relief, patients face logistical, financial, and emotional challenges.
The study, led by Dr. Camilla Graham and conducted in collaboration with experts from the University of Alabama, Vanderbilt University Medical Center, and the Pulmonary Fibrosis Foundation, emphasizes the need for enhanced disease awareness, streamlined diagnosis, and patient-centered treatment approaches.
PureTech Health reported strong results for 2024, highlighting significant clinical and financial achievements. The company's wholly-owned deupirfenidone showed positive Phase 2b results in IPF treatment, while LYT-200 demonstrated promising outcomes in cancer trials. A major milestone was the FDA approval of Cobenfy for schizophrenia.
The company maintained a robust financial position with $366.8 million in cash at PureTech level as of December 2024, providing operational runway into 2027. Notable achievements include their Founded Entity, Seaport Therapeutics, raising over $325 million.
Key developments include positive results from the ELEVATE IPF trial, with deupirfenidone showing potential to stabilize lung function. The company plans to initiate Phase 3 trials by end of 2025, subject to FDA feedback. PureTech's innovation engine has produced 29 therapeutic candidates, with three achieving FDA approval.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) has announced it will release its Annual Report and Accounts along with financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025.
The company will host a presentation and conference call to discuss the results at 9:00 AM EDT / 2:00 PM BST on the same day. Investors and interested parties can access the webcast presentation through PureTech's investor relations website.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) has announced the appointment of Peel Hunt as its Joint UK Corporate Broker. The firm will work alongside existing broker UBS to provide corporate broking services.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has confirmed it is in discussions with Nordic Capital Epsilon regarding a potential cash offer to acquire PureTech's entire share capital. Nordic Capital must announce a firm intention to make an offer or declare no intention by 5:00 PM London time on May 5, 2025.
The deadline may be extended with Takeover Panel consent. As of April 4, 2025, PureTech had 240,189,449 ordinary shares outstanding (excluding treasury shares). J.P. Morgan Securities is acting as financial adviser exclusively for PureTech in this matter.
The company emphasizes there is no certainty that any firm offer will be made or regarding potential terms. This announcement was made without Nordic Capital's consent.
PureTech Health (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company focused on developing treatments for devastating diseases, has announced its participation in the Leerink Partners Global Healthcare Conference.
The company's Chief Executive Officer, Bharatt Chowrira, PhD, JD, and Co-founder and President, Eric Elenko, PhD, will engage in a fireside chat on Tuesday, March 11, 2025, at 1:00pm EDT.
Investors and interested parties can access a webcast of the presentation through PureTech's investor relations website at https://investors.puretechhealth.com.
PureTech's Founded Entity, Seaport Therapeutics, published new research in Molecular Pharmaceutics showcasing enhanced drug transport capabilities of their Glyph platform. The study demonstrated up to 55% drug absorption via lymphatics, marking the highest reported level of lymphatic transport for the studied immunomodulatory drug.
The research evaluated modifications to mycophenolic acid (MPA), revealing that a new phenol attachment point achieved superior lymphatic transport and up to two-fold higher release in lymph nodes compared to previously reported attachment methods. The Glyph platform enables drugs to be absorbed through the intestinal lymphatic system like dietary fats, potentially benefiting therapeutic molecules with high first-pass metabolism issues.
PureTech's Founded Entity, Vedanta Biosciences, published additional Phase 2 results for VE303, their lead candidate for preventing recurrent Clostridioides difficile infection (rCDI), in Nature Medicine. The study showed VE303, a first-in-class Live Biotherapeutic Product consisting of eight bacterial strains, was well-tolerated and reduced CDI recurrence odds by over 80% compared to placebo.
The new analyses revealed that VE303 works through multiple mechanisms, including restoring healthy gut microbial community, decreasing inflammation, and increasing protective metabolites. The research identified predictors of VE303 colonization and clinical response, showing that strain abundance was predictive of remaining recurrence-free.
These findings informed the design of the ongoing global Phase 3 RESTORATiVE303 study, with topline data expected in 2026.
PureTech Health (PRTC) announced that the FDA has granted Fast Track designation to LYT-200, their first-in-class anti-galectin-9 monoclonal antibody, for treating acute myeloid leukemia (AML). This follows previous FDA recognitions including Orphan Drug designation for AML and Fast Track designation for head and neck cancers.
LYT-200 is currently being evaluated in two Phase 1/2 clinical trials: one for hematological malignancies (AML and high-risk myelodysplastic syndrome) and another for advanced/metastatic solid tumors. The drug has shown favorable safety profiles in both trials, with early signals of clinical activity both as a monotherapy and in combination with other treatments.
The treatment works by directly killing cancer cells through apoptosis and DNA damage while reactivating the immune system's anti-cancer mechanisms. PureTech plans to advance LYT-200 through its Founded Entity, Gallop Oncology.
FAQ
What is the current stock price of Puretech Health (PRTC)?
What is the market cap of Puretech Health (PRTC)?
